Home > Insider Trading > Filing (0001012975-19-000449)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1744659	Akero Therapeutics Inc.	AKRO	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1278411	S Corey Goodman	1700 Owens Street, Suite 595 San Francisco CA 94158	No	No	Yes	No
1329161	J Robert Adelman	1700 Owens Street, Suite 595 San Francisco CA 94158	No	No	Yes	No
1634632	L.p. Ii Fund Strategic Global Venbio	1700 Owens Street, Suite 595 San Francisco CA 94158	No	No	Yes	No
1729408	Venbio Global Strategic Gp Ii, Ltd.	1700 Owens Street, Suite 595 San Francisco CA 94158	No	No	Yes	No
1729409	Venbio Global Strategic Gp Ii, L.p.	1700 Owens Street, Suite 595 San Francisco CA 94158	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-06-24	250,000	$16.00	250,000	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2019-06-24	3,469,759	$0.00	3,719,759	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-06-24	235,099	$0.00	3,954,858	No	4	C	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-06-24	10,666,667	$0.00	3,469,759	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-06-24	722,737	$0.00	235,099	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

On June 24, 2019, venBio Global Strategic Fund II, L.P. purchased 250,000 shares of common stock of the Issuer at a price of $16.00 per share in the Issuer's initial public offering.
These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.
Represents the total number of shares of common stock received by venBio Global Strategic Fund II, L.P. upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.
Represents the total number of shares of common stock received by venBio Global Strategic Fund II, L.P. upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.